ArticleMicrobiology spectrum2023
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 9 citations in OpenAlex.
- Lanosterol synthase inhibition as a potential approach for re-sensitizing triazole-resistantmBio · 2026Article
- A long noncoding RNA regulates in vitro and in vivo triazole antifungal susceptibility in Aspergillus fumigatus.Genetics · 2026Article
- Laboratory Diagnostics of Aspergillosis: Present State and Future Directions.Journal of fungi (Basel, Switzerland) · 2026Review
- Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026Review
- Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance.The Journal of antimicrobial chemotherapy · 2026Article
- Sexual reproduction and the polygenic architecture of azole resistance in agricultural populations ofFrontiers in microbiology · 2026Article
- A long non-coding RNA regulates triazole antifungal susceptibility and virulence inbioRxiv : the preprint server for biology · 2025Article
- Regulation of Ergosterol Biosynthesis in Pathogenic Fungi: Opportunities for Therapeutic Development.Microorganisms · 2025Review
- Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Molecular Identification ofInfection and drug resistance · 2025Article
- Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches.Journal of fungi (Basel, Switzerland) · 2024Review
- A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1.Nature communications · 2024Article
- Epidemiology and Azole Resistance of Clinical Isolates ofInfection and drug resistance · 2024Article
- Occurrence of Aspergillus fumigatus azole resistance in soils from Switzerland.Medical mycology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Aspergillus fumigatus is a ubiquitous environmental mold that can cause severe disease in immunocompromised patients and chronic disease in individuals with underlying lung conditions. Triazoles are the most widely used class of antifungal drugs to treat A. fumigatus infections, but their use in the clinic is threatened by the emergence of triazole-resistant isolates worldwide, reinforcing the need for a better understanding of resistance mechanisms. The predominant mechanisms of A. fumigatus triazole resistance involve mutations affecting the promoter region or coding sequence of the target enzyme of the triazoles, Cyp51A. However, triazole-resistant isolates without
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.